Mohit Bansal

Biogen Inc’s (NASDAQ: BIIB) base business seems to be worth more than what the Street estimates, and it is possible that investors are not properly valuing royalty streams coming to the company, which contributes 15% of current revenues and 40% of the valuation, according to Wells Fargo. The...

Shares of Coherus Biosciences Inc (NASDAQ: CHRS) were trading down more than 15 percent on Monday following news that the Patent Trials and Appeals Board didn't institute their Intellectual Property Rights (IPR) '166 over Abbvie’s Humira. Amid the price action, Citi analyst Mohit...

Neulasta and Humira biosimilar clarity over next 12 months could lend significant upside to shares of Coherus Biosciences Inc (NASDAQ: CHRS), Citi’s Mohit Bansal said in a report. He maintained a Buy rating on the company, with a price target of $36. Although Coherus Biosciences is among...